Latent tuberculosis infection testing in people with compromised immunity prior to biologic therapy : a review of diagnostic accuracy, clinical utility, and guidelines / Calvin Young, Melissa Severn
There is no established gold standard technique for diagnosing latent TB infection. The most commonly used screening methods are the tuberculin skin test (TST) and interferon gamma release assays (IGRAs); however, these diagnostic tools have limited sensitivity and specificity. The objective of the current report is to evaluate the evidence regarding the diagnostic accuracy and clinical utility of the TST for patients with compromised immunity prior to initiating biologic treatment. Additionally, evidence-based guidelines regarding testing for latent TB infection in patients with compromised immunity prior to initiating biologic therapy will be reviewed. This report expands upon a previously completed CADTH report..
| Medienart: |
E-Book |
|---|
| Erscheinungsjahr: |
December 1, 2020 |
|---|---|
| Erschienen: |
Ottawa: Canadian Agency for Drugs and Technologies in Health ; December 1, 2020 |
| Reihe: |
CADTH rapid response report: summary with critical appraisal |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Young, Calvin [VerfasserIn] |
|---|
| Links: |
www.ncbi.nlm.nih.gov [teilw. kostenfrei] |
|---|
| Themen: |
Biological Therapy |
|---|
| Anmerkungen: |
Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed September 7, 2021) |
|---|
| Umfang: |
1 online resource (1 PDF file (47 pages)) ; illustration. |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
1776329066 |
|---|
| LEADER | 01000cam a22002652 4500 | ||
|---|---|---|---|
| 001 | 1776329066 | ||
| 003 | DE-627 | ||
| 005 | 20230428085632.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211108s2020 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)1776329066 | ||
| 035 | |a (DE-599)KEP069203679 | ||
| 035 | |a (OCoLC)1284293026 | ||
| 035 | |a (NCBI)9917766723406676 | ||
| 035 | |a (EBP)069203679 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Young, Calvin |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Latent tuberculosis infection testing in people with compromised immunity prior to biologic therapy |b a review of diagnostic accuracy, clinical utility, and guidelines |c Calvin Young, Melissa Severn |
| 264 | 1 | |a Ottawa |b Canadian Agency for Drugs and Technologies in Health |c December 1, 2020 | |
| 300 | |a 1 online resource (1 PDF file (47 pages)) |b illustration. | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 490 | 0 | |a CADTH rapid response report: summary with critical appraisal | |
| 500 | |a Includes bibliographical references. - Description based on online resource; title from PDF title page (viewed September 7, 2021) | ||
| 520 | |a There is no established gold standard technique for diagnosing latent TB infection. The most commonly used screening methods are the tuberculin skin test (TST) and interferon gamma release assays (IGRAs); however, these diagnostic tools have limited sensitivity and specificity. The objective of the current report is to evaluate the evidence regarding the diagnostic accuracy and clinical utility of the TST for patients with compromised immunity prior to initiating biologic treatment. Additionally, evidence-based guidelines regarding testing for latent TB infection in patients with compromised immunity prior to initiating biologic therapy will be reviewed. This report expands upon a previously completed CADTH report. | ||
| 650 | 2 | |a Latent Tuberculosis |x diagnosis | |
| 650 | 2 | |a Immunocompromised Host | |
| 650 | 2 | |a Biological Therapy | |
| 650 | 2 | |a Practice Guidelines as Topic | |
| 655 | 2 | |a Review | |
| 700 | 1 | |a Severn, Melissa |e verfasserin |4 aut | |
| 710 | 2 | |a Canadian Agency for Drugs and Technologies in Health, |e MitwirkendeR |4 ctb | |
| 856 | 4 | 0 | |u https://www.ncbi.nlm.nih.gov/books/NBK567073/ |m X:NCBI |x Verlag |z teilw. kostenfrei |
| 912 | |a ZDB-193-NCB | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a ISIL_DE-18 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_22_i06404 | ||
| 912 | |a GBV_ILN_40 | ||
| 912 | |a ISIL_DE-7 | ||
| 912 | |a GBV_ILN_74 | ||
| 912 | |a ISIL_DE-354 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a ISIL_DE-25 | ||
| 912 | |a GBV_ILN_2009 | ||
| 912 | |a ISIL_DE-180 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a ISIL_DE-15 | ||
| 951 | |a BO | ||
| 980 | |2 22 |1 01 |x 0018 |b 399985717X |h h64 NCBI |y zi06404 |z 08-11-21 | ||
| 980 | |2 40 |1 01 |x 0007 |b 3999856092 |h OLR-NCB-BOOKSHELF |y xsn |z 08-11-21 | ||
| 980 | |2 74 |1 01 |x 0354 |b 3999855010 |c 09 |f E-Bibl |d EM 0000 |e --%%-- |j --%%-- |y ze |z 08-11-21 | ||
| 980 | |2 2003 |1 01 |x DE-25 |b 3999632933 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 08-11-21 | ||
| 980 | |2 2009 |1 01 |x DE-180 |b 3999635355 |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 08-11-21 | ||
| 980 | |2 2010 |1 01 |x DE-15 |b 3999635363 |c 00 |f --%%-- |d --%%-- |e --%%-- |j n |k Elektronischer Volltext - Open Access |y l01 |z 08-11-21 | ||
| 981 | |2 22 |1 01 |x 0018 |r https://www.ncbi.nlm.nih.gov/books/NBK567073/ | ||
| 981 | |2 40 |1 01 |x 0007 |y Volltext, Open Access |r https://www.ncbi.nlm.nih.gov/books/NBK567073/ | ||
| 981 | |2 74 |1 01 |x 0354 |r https://www.ncbi.nlm.nih.gov/books/NBK567073/ | ||
| 981 | |2 2003 |1 01 |x DE-25 |r https://www.ncbi.nlm.nih.gov/books/NBK567073/ | ||
| 981 | |2 2010 |1 01 |x DE-15 |y Online-Zugriff |r https://www.ncbi.nlm.nih.gov/books/NBK567073/ | ||
| 985 | |2 22 |1 01 |x 0018 |a h64 ebook | ||
| 985 | |2 74 |1 01 |x 0354 |a EM 0000 | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 NCBI | ||
| 995 | |2 22 |1 01 |x 0018 |a h64 freie Ressource | ||
| 995 | |2 40 |1 01 |x 0007 |a OLR-NCB-BOOKSHELF | ||